We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Single Blood Test Could Detect Different Types of Cancer at Early Stages

By LabMedica International staff writers
Posted on 14 May 2025

Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. More...

While these screenings have been successful in reducing death rates from these cancers, they can sometimes lead to false positives and overdiagnosis. A groundbreaking single blood test, capable of detecting chemical signals from multiple types of cancer, may now be able to identify the disease in its early stages, making it easier to treat for nearly 50% of patients.

A study led by Queen Mary University of London (QMUL, London, UK) sought to determine if a multi-cancer early detection (MCED) test, administered annually or every two years, could detect cancer at an early stage and thereby improve patient outcomes. The study’s findings, published in BMJ Open, suggested that MCED tests have the potential to identify 31–49% of cancers at stages I-II that would otherwise be detected only at stages III-IV. The researchers used an existing disease progression model for various cancers to predict the effects of regular screening with an MCED test on cancer diagnosis times and patient survival under different screening schedules. The cancers included in the study span a wide range, including those of the anus, bladder, breast, cervix, bowel/rectum, esophagus, gallbladder, head and neck, kidney, liver/bile duct, lung, ovary, pancreas, prostate, sarcoma (soft tissues/bone), stomach, thyroid, uterus, and the blood cancers such as leukemia, lymphoma, melanoma, and myeloid neoplasms.

The modeling results indicated that all MCED screening intervals showed better early-stage detection rates compared to standard care alone. The shift to earlier stages of diagnosis was particularly significant for tumors with faster growth, which tend to remain at stage I for 2 to 4 years before progressing. In contrast, tumors with fast, aggressive growth (progressing within 1 to 2 years from stage I) showed a smaller effect from early detection. The study found that annual MCED screening yielded more diagnoses and prevented more deaths within 5 years than screening every two years. In a scenario involving 392 individuals diagnosed annually with aggressive cancers that would lead to death within 5 years, biennial MCED screening could have prevented 54 (14%) deaths, while annual MCED screening could have prevented 84 (21%) deaths.

“When choosing how often to offer different type of cancer screening there is a balance to be made between preventing more cancer deaths and obtaining the greatest benefit for the costs and inconvenience of screening. Generally, the faster the cancer develops the more frequently one needs to screen,” said Professor Peter Sasieni, Professor of Cancer Epidemiology, Centre Co-Lead for the Centre for Cancer Screening, Prevention and Early Diagnosis, at QMUL. “We modelled what might be appropriate for a screening test that can detect all types of cancer. If screening works, even screening once every three years would prevent a substantial proportion of advanced stage cancers, but more frequent screening is needed to maximise the potential benefit. Depending on pricing, it seems likely that annual testing might deemed the most appropriate for blood-based multi-cancer screening.”


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.